TY - JOUR DO - 10.31373/ejtcm/137918 TI - Urolithins and their possible implications for diabetic kidney T2 - European Journal of Translational and Clinical Medicine AU - Kotewicz, Milena AU - Lewko, Barbara PY - 2022 DA - 2022/02/21 PB - Medical University of GdaƄsk SP - 53 EP - 63 VL - 5 IS - 1 KW - urolithins, diabetes, kidney, podocytes LA - en AB - The increasing prevalence of diabetic kidney disease (DKD), a common complication of type 1 and type 2 diabetes, is becoming a leading risk factor of developing end stage renal disease (ESRD). The multiple mechanisms involved in renal tissue damage are a challenge for effective targeted therapy. Urolithins are metabolites generated by gut microbiota upon dietary intake of plant-derived ellagitannins. Multidirectional effects of these compounds include their anti-inflammatory, antioxidant, anti-proliferatory, anti-migratory and antiglycative properties that are mediated by modulation of signaling pathways and gene expression. Biochemical properties of urolithins indicate their capacity to regulate numerous mechanisms responsible for developing the hyperglycemia-induced tissue injury. The potentially beneficial effects of urolithins on podocytes, the most vulnerable renal cells should be particularly considered. The purpose of this review is to provide the evidence from the in vivo and in vitro studies showing that urolithin-based therapy could be a useful tool for protecting the kidneys from damage in diabetes. LK - https://ejtcm.gumed.edu.pl/articles/137918 UR - https://doi.org/10.31373/ejtcm/137918 ER -